Pietrangelo, Antonello

Hereditary Hemochromatosis — A New Look at an Old Disease

Pietrangelo, A. (2004) · New England Journal of Medicine

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 992

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 939

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

De Biasi, S., Meschiari, M., Gibellini, L., Bellinazzi, C., Borella, R., Fidanza, L., Gozzi, L., Iannone, A., Lo Tartaro, D., Mattioli, M., et al. (2020) · Nature Communications

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 789

BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism

Andriopoulos Jr, B., Corradini, E., Xia, Y., Faasse, S. A., Chen, S., Grgurevic, L., Knutson, M. D., Pietrangelo, A., Vukicevic, S., Lin, H. Y., et al. (2009) · Nature Genetics

Iron Metabolism and DisordersIron and Steelmaking Processes

Cited by 769

Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment

Pietrangelo, A. (2010) · Gastroenterology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 615

Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene

Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 557

Haemochromatosis

Brissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O. (2018) · Nature Reviews Disease Primers

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 430

STAT3 Is Required for IL-6-gp130–Dependent Activation of Hepcidin In Vivo

Pietrangelo, A., Dierssen, U., Valli, L., Garuti, C., Rump, A., Corradini, E., Ernst, M., Klein, C., & Trautwein, C. (2007) · Gastroenterology

Iron Metabolism and DisordersCytokine Signaling Pathways and Interactions

Cited by 315

ER Stress Controls Iron Metabolism Through Induction of Hepcidin

Vecchi, C., Montosi, G., Zhang, K., Lamberti, I., Duncan, S. A., Kaufman, R. J., & Pietrangelo, A. (2009) · Science

Iron Metabolism and DisordersEndoplasmic Reticulum Stress and Disease

Cited by 310

Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload

Zoller, H., Weiss, G., Theurl, I., Koch, R. O., Vogel, W., Obrist, P., Pietrangelo, A., Montosi, G., & Haile, D. J. (2001) · Gastroenterology

Iron Metabolism and DisordersTrace Elements in Health

Cited by 304

Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription

Nishina, S., Hino, K., Korenaga, M., Vecchi, C., Pietrangelo, A., Mizukami, Y., Furutani, T., Sakai, A., Okuda, M., Hidaka, I., et al. (2008) · Gastroenterology

Iron Metabolism and DisordersHepatitis C virus research

Cited by 259

Heterogeneity of hemochromatosis in Italy

Piperno, A., Sampietro, M., Pietrangelo, A., Arosio, C., Lupica, L., Montosi, G., Vergani, A., Fraquelli, M., Girelli, D., & Pasquero, P. (1998) · Gastroenterology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 235

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 220

Hemochromatosis: An endocrine liver disease

Pietrangelo, A. (2007) · Hepatology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 212

Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene☆

Gordeuk, V. R., Caleffi, A., Corradini, E., Ferrara, F., Jones, R. A., Castro, O., Onyekwere, O., Kittles, R., Pignatti, E., Montosi, G., et al. (2003) · Blood Cells, Molecules, and Diseases

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 198

Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice

Corradini, E., Meynard, D., Wu, Q., Chen, S., Ventura, P., Pietrangelo, A., & Babitt, J. L. (2011) · Hepatology

Iron Metabolism and DisordersTGF-β signaling in diseases

Cited by 194

Iron and the liver

Pietrangelo, A. (2016) · Liver International

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 174

Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis

Zoller, H., Pietrangelo, A., Vogel, W., & Weiss, G. (1999) · The Lancet

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 167

Ferroportin disease: pathogenesis, diagnosis and treatment

Pietrangelo, A. (2017) · Haematologica

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 151

Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB

Sonnweber, T., Nachbaur, D., Schroll, A., Nairz, M., Seifert, M., Demetz, E., Haschka, D., Mitterstiller, A.-M., Kleinsasser, A., Burtscher, M., et al. (2014) · Gut

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 145

Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin

Pietrangelo, A. (2015) · Gastroenterology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 136

Ferroportin disease: a systematic meta-analysis of clinical and molecular findings

Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology

Iron Metabolism and DisordersNeurological diseases and metabolism

Cited by 133

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia

Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., Caruso, V., Pietrangelo, A., Longo, F., Tartaglione, I., et al. (2019) · Blood

Hemoglobinopathies and Related DisordersIron Metabolism and Disorders

Cited by 119

Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice

Canali, S., Core, A. B., Zumbrennen-Bullough, K. B., Merkulova, M., Wang, C.-Y., Schneyer, A. L., Pietrangelo, A., & Babitt, J. L. (2016) · Endocrinology

Iron Metabolism and DisordersTGF-β signaling in diseases

Cited by 113